Tacrolimus conversion in kidney transplant recipients: Analysis of 107 patients

Transplantation Proceedings

Volumn 36, Issue 1, 2004, Pages 144-147

  Yagmurdur M C ^a   Sevmis, S ^a   Emiroglu R ^a   Moray, G ^a   Bilgin, N ^a   Haberal, M ^a  

^a BASKENT UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CREATININE; CYCLOSPORIN; GLUCOSE; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; STEROID; TACROLIMUS;

ADULT; CONFERENCE PAPER; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIABETES MELLITUS; DRUG BLOOD LEVEL; DRUG INDICATION; DRUG RESPONSE; DRUG WITHDRAWAL; EPILEPSY; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; GRAFT FAILURE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KAPOSI SARCOMA; KIDNEY DISEASE; KIDNEY GRAFT; KIDNEY GRAFT REJECTION; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; NEPHROTOXICITY; NOCARDIOSIS; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; RECIPIENT; SEPSIS;

EID: 0842281682     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transproceed.2003.11.044     Document Type: Conference Paper

References (16)

1. Goto T., Kino T., Hatanaka M., et al. Historical perspectives. Transplant Proc. 23:1991;2713.
2. Neylan J.F. Racial differences in renal transplantation after immunosuppression with tacrolimus versus cyclosporine. Transplantation. 65:1998;515.
3. Pirsch J.D., Miller J., Deierhoi M.H., et al. A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation. Transplantation. 63:1997;977.
4. Undre N.A., van Hoff J., Christians M., et al. Low systemic exposure to tacrolimus correlates with acute rejection. Transplant Proc. 31:1999;296.
5. Scantlebury V., Shapiro R., Fung J., et al. New onset of diabetes in FK506- vs cyclosporine-treated kidney transplant recipients. Transplant Proc. 23:1991;3169.
6. Fernandez L.A., Lehmann R., Luzi L., et al. The effects of maintenance doses of FK506 vs cyclosporine A on glucose and lipid metabolism after orthotopic liver transplantation. Transplantation. 68:1999;1532.
7. Jordan M.L., Naraghi R., Shapiro R., et al. Tacrolimus rescue therapy for renal allograft rejection: five-year experience. Transplantation. 63:1997;223.
8. Fulton B., Markham A. Mycophenolate mofetil a review of its pharmacodynamic and pharmacokinetic properties and clinical efficacy in renal transplantation . Transplant Proc. 26:1994;3205.
9. Miles A.M., Sumrani N., Horowitz R., et al. Diabetes mellitus after renal transplantation. Transplantation. 65:1998;380.
10. Redmon J.B., Olson L.K., Armstrong M.B., et al. Effects of tacrolimus (FK506) on human insulin gene expression, insulin mRNA levels, and insulin secretion in HIT-T15 cells. J Clin Invest. 98:1996;2786.
11. Shapiro R., Fung J.J., Jain A.B., et al. The side effects of FK506 in humans. Transplant Proc. 23:1990;35.
12. Johnson C., Ahsan N., Gonwa T., et al. Randomized trial of tacrolimus (Prograf) in combination with azathioprine or mycophenolate mofetil versus cyclosporine (Neoral) with mycophenolate mofetil after cadaveric kidney transplantation. Transplantation. 69:2000;834.
13. Karakayali H., Yagmurdur M.C., Emiroglu R., et al. Effects of mycophenolate mofetil on the gastrointestinal system and kidney graft function early experience at one center . Transplant Proc. 34:2002;2093.
14. Colak T., Karakayali H., Yagmurdur M.C., et al. Effect of conversion from cyclosporine to tacrolimus in renal transplant recipients. Transplant Proc. 34:2002;2081.
15. noll G.A., Bell R. Tacrolimus versus cyclosporine for immunosuppression in renal transplantation meta analysis of randomized trials . BMJ. 318:1999;1104.
16. Woodle E.S., Thistletwait J.R., Gordon J.H., et al. A multicenter trial of FK506 (tacrolimus) therapy in refractory acute renal allograft rejection. Transplantation. 62:1996;594.